Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis

Oncology

Volumn 66, Issue 5, 2004, Pages 358-364

  Tominaga, Kazunari ^a   Higuchi, Kazuhide ^a   Okazaki, Hirotoshi ^a   Suto, Reiko ^a   Hamaguchi, Masaki ^a   Tanigawa, Tetsuya ^a   Sasaki, Eiji ^a   Shiba, Masatsugu ^a   Watanabe, Toshio ^a   Fujiwara, Yasuhiro ^a   Oshitani, Nobuhide ^a   Matsumoto, Takayuki ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Pharmacokinetics, S 1; Renal failure; S 1, oral fluorouracil antitumor drug

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; FLUOROURACIL; OXONATE POTASSIUM; TEGAFUR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CALCULATION; CANCER GROWTH; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOSCOPY; HEMODIALYSIS; HUMAN; LIVER METASTASIS; MAINTENANCE THERAPY; MALE; MEASUREMENT; PATIENT MONITORING; PRIORITY JOURNAL; REMISSION; STOMACH CANCER;

ADMINISTRATION, ORAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER NEOPLASMS; MALE; OXONIC ACID; PYRIDINES; RENAL DIALYSIS; STOMACH NEOPLASMS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4444349739     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079483     Document Type: Article

References (19)

1. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-2206.
2. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606.
3. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
4. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-197.
5. Tsukioka Y, Matsumura Y, Hamaguchi T, Goto M, Muro K, Yamada Y, Shirao K: Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: A case report. Jpn J Clin Oncol 2001;31:450-453.
6. Iwazawa T, Kinuta M, Yano H, Matsui S, Tamagaki S, Yasue A, Okada K, Kanoh T, Tono T, Nakano Y, Okamoto S, Monden T: An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection. Gastric Cancer 2002;5:96-101.
7. Watanabe S, Tanaka T, Takeuchi T, Takabayashi H, Hirayama Y: Advanced gastric cancer with liver metastases successfully treated with S-1. Int J Clin Oncol 2002;7:326-329.
8. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-2005.
9. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, ed 13. Tokyo, Kanehara, 1992.
10. Takahashi H, Tono T, Tamagaki S, Yasue A, Okada K, Kano T, Iwazawa T, Matsui S, Nakano Y, Yano H, Kinuta M, Matsushita M, Okamura J, Monden T: Usefulness of hepatic arterial infusion chemotherapy for liver metastasis in gastric cancer (in Japanese). Gan To Kagaku Ryoho 2001;28:1724-1727.
11. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent, in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 2002;50:25-32.
12. Kondo Y, Sakaguchi H, Nakamuro M, Kawamura J, Takami M, Kotake Y: Successful TS-1 therapy in a patient with non-resectable gastric cancer and renal dysfunction (in Japanese). Gan To Kagaku Ryoho 2000;27:2249-2253.
13. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I: Phase I study of S-1. S-1 Study Group. (In Japanese.) Gan To Kagaku Ryoho 1997;24:2253-2264.
14. Maruyama M, Irie T, Yoshida T, Nagahama T, Sugano N, Ebuchi M: Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis (in Japanese). Gan To Kagaku Ryoho 1999;26:2241-2245.
15. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS: Increased incidence of malignancy during chronic renal failure. Lancet 1975;1:883-886.
16. Miach PJ, Dawborn JK, Xipell J: Neoplasia in patients with chronic renal failure on long-term dialysis. Clin Nephrol 1976;5:101-104.
17. Sutherland GA, Glass J, Gabriel R: Increased incidence of malignancy in chronic renal failure. Nephron 1977;18:182-184.
18. Ito T, Tanaka I, Kadoya T, Kimura M, Ooshiro T, Ooishi K, Tanaka J, Yorioka N: Screening for gastroenterological malignancies in new and maintenance dialysis patients. J Gastroenterol 1999;34:35-40.
19. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C: Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002;20:1683-1691.